Who are Darzalex Faspro's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Darzalex, Darzalex, SARCLISA, DARATUMUMAB (DARZALEX®), Daratumumab and corticosteroid treatment, SCT800 and Daratumumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daratumumab-and-hyaluronidase-fihj.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Darzalex Faspro — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Darzalex Faspro (daratumumab-and-hyaluronidase-fihj) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD38-directed Cytolytic Antibody [EPC]. Area: Oncology.

marketed CD38-directed Cytolytic Antibody [EPC] CD38 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Darzalex Faspro (daratumumab-and-hyaluronidase-fihj) — Pfizer. Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Darzalex Faspro TARGET	daratumumab-and-hyaluronidase-fihj	Pfizer	marketed	CD38-directed Cytolytic Antibody [EPC]	CD38	2020-01-01
Darzalex	daratumumab	Johnson & Johnson	marketed	Monoclonal antibody	CD38	2015-01-01
Darzalex	Darzalex	Shanghai Henlius Biotech	marketed		Lymphocyte differentiation antigen CD38
SARCLISA	ISATUXIMAB-IRFC	SANOFI AVENTIS US	marketed	CD38-directed Cytolytic Antibody [EPC]	Lymphocyte differentiation antigen CD38
DARATUMUMAB (DARZALEX®)	DARATUMUMAB (DARZALEX®)	Hospices Civils de Lyon	marketed	CD38-targeting monoclonal antibody	CD38
Daratumumab and corticosteroid treatment	Daratumumab and corticosteroid treatment	Institute of Hematology & Blood Diseases Hospital, China	marketed	Monoclonal antibody (CD38-targeting) combined with corticosteroid	CD38
SCT800 and Daratumumab	SCT800 and Daratumumab	Institute of Hematology & Blood Diseases Hospital, China	marketed	Bispecific T-cell engager (SCT800); CD38-targeting monoclonal antibody (Daratumumab)	CD19 and CD3 (SCT800); CD38 (Daratumumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD38-directed Cytolytic Antibody [EPC] class)

· 1 drug in this class
Pfizer · 1 drug in this class
SANOFI AVENTIS US · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Darzalex Faspro — Competitive Intelligence Brief. https://druglandscape.com/ci/daratumumab-and-hyaluronidase-fihj. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab